REAGAN DUNCAN: Open Payments
NPI 1558033936 · LAMPASAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$472 in 24 payments from 10 companies in 2025. Trend: 2023 $877 · 2024 $1,026 · 2025 $472
Food & beverage: $472
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $142 |
| Corium, LLC | 3 | $78 |
| PFIZER INC. | 3 | $71 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $31 |
| Abbott Laboratories | 1 | $26 |
| Verona Pharma, Inc. | 1 | $19 |
| Exact Sciences Corporation | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $14 |
Products named: Ozempic, Azstarys, ELIQUIS, GEMTESA, TRELEGY ELLIPTA, XIFAXAN, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, PREVNAR 20.
Industry payments across TX — which companies pay providers there.
